Seeking Alpha

nunbid

nunbid
Send Message
View as an RSS Feed
View nunbid's Comments BY TICKER:
Latest  |  Highest rated
  • Arena - What Now? [View article]
    VVUS is the winner in this sector, not ARNA. ARNA now cashing in on secondary. Company wins, perma-shareholders lose. See DNDN, 2007-2012.
    May 16 04:24 AM | Likes Like |Link to Comment
  • Arena - What Now? [View article]
    You mean when an FDA panel recommended approval overwhemingly in March 2007, but the 2 negative voters lobbied the FDA aggressively, and conflictedly, leading to the FDA rejecting it for more studies/data in May 2007? Stock crashed. 2010 went much better. Then stock crashed again.
    May 16 04:23 AM | Likes Like |Link to Comment
  • Pre-ASCO Interview With ImmunoCellular Therapeutics CEO Dr. Singh [View article]
    "our phase I data has demonstrated a survival improvement of about 24 months"

    MAJOR RED FLAG WHEN YOUR CEO TOUTS PHASE 1 DATA AS PROVING ANYTHING.

    What an idiot and so are inexperienced biotech gamblers for believing this nonsense.
    May 10 06:35 AM | Likes Like |Link to Comment
  • ImmunoCellular's ICT-107 Touted As A Stand Out Therapeutic Vaccine [View article]
    CEO comparing Phase 1 data under controls that are completely invalid against DNDN's phase 3 trials. OB stock. Pumped on message boards, SA, twitter, for years by known paid pumpers. Stay away from this scam.
    Nov 1 10:17 AM | 1 Like Like |Link to Comment
  • Savient Pharmaceuticals: Value Play Or Value Trap? [View article]
    Krystexxa will eventually bring in about $300mm annually but it will take a couple more years to ramp up. 2012 will be first year with reimbursement process streamlined (J code not in place until then) and give doctors confidence that they'll get paid in 30 days. Remind you of any other 2011 biotech disasters? DNDN, HGSI. All will soar in 2012. Just not back to where they were in 2010. Same for SVNT.
    Oct 14 04:27 PM | Likes Like |Link to Comment
  • Savient Pharmaceuticals: Value Play Or Value Trap? [View article]
    The guys that rejected buyout offers in the $20's are gone. New CEO has options around $8 as does the rest of the new management team.

    They'd take a buyout offer in the mid-teens and will be forced to take it by shareholders. This will happen in 2012 after reimbursement issues clear up.

    2012 will see several 2011 biotech dogs recover some of their share price highs, but sell out well below them to big pharmas. Count HGSI and DNDN on that list too. they'll sell out for $20-ish.
    Oct 14 04:24 PM | Likes Like |Link to Comment
  • SodaStream International May Have Just Popped [View article]
    Where are these "save $5" coupons? Never seen them and shop BBB often
    Aug 16 10:16 AM | Likes Like |Link to Comment
  • SodaStream International May Have Just Popped [View article]
    CO2 costs over $12 w/coupon at BBB. $15 w/o.
    Aug 15 01:28 PM | Likes Like |Link to Comment
  • Dendreon Earnings Preview: It's All About Provenge Sales [View article]
    I've downgraded DNDN from 27 to 7, lol.
    Aug 5 03:45 PM | 1 Like Like |Link to Comment
  • Dendreon Earnings Preview: It's All About Provenge Sales [View article]
    Have you seen what happened to HGSI? Time to recalibrate the $4B-$6B biotech's. And HGSI is the one that's supposed to have a takeover chance soon. But look at it today. Don't underestimate the power of plunging a stock.
    Aug 3 01:32 PM | Likes Like |Link to Comment
  • Dendreon Earnings Preview: It's All About Provenge Sales [View article]
    NWBO? You guys don't give up. You're not the next DNDN, neither is IMUC. Let the OTC BB scams continue. Dendreon will report $60M revenue, guide to same as previous guidance, and stock will sell off. Shorty needs to cover low and will panic down the stock and spin the news as bad. Adam will just love...to bash....it in the morning. Even Favus is poking his crooked head up again. Load up DNDN at 27.
    Aug 3 01:30 PM | 1 Like Like |Link to Comment
  • Dendreon Earnings Preview: It's All About Provenge Sales [View article]
    Already hit $33's today. If Dendreon gets analenge to phase 2 it would be their first drug besides Provenge, and since the 1990's to get to phase 2. Great stock to buy at $27 and sell at $40, repeatedly.
    Aug 3 01:28 PM | 1 Like Like |Link to Comment
  • Dendreon Earnings Preview: It's All About Provenge Sales [View article]
    We'll see.
    Aug 2 08:47 AM | 1 Like Like |Link to Comment
  • Dendreon Earnings Preview: It's All About Provenge Sales [View article]
    looking forward to buying at $27
    Aug 1 11:01 PM | 1 Like Like |Link to Comment
  • Ancestry.com: Selling at a Discount in the Low 30s [View article]
    So any stock with a lower PE than $NFLX is "selling at a discount". Wow, great research.
    Aug 1 07:33 PM | Likes Like |Link to Comment
COMMENTS STATS
79 Comments
72 Likes